Clarity Pharmaceuticals launches $121 million fully underwritten equity raising

Latest News

Australian clinical-stage radiopharmaceutical company Clarity Pharmaceuticals (ASX:CU6) has announced a fully underwritten $121 million equity raising comprising a pro-rata accelerated non-renounceable entitlement offer and placement to institutional investors.

The fully underwritten $121 million equity raising consists of a $101 million placement to institutional investors and a $20 million pro rata accelerated non-renounceable entitlement offer to existing eligible shareholders in Australia and New Zealand.

The company said the proceeds will advance its clinical portfolio and strengthen the balance sheet.

Post completion of the offer, it will have a proforma cash balance of A$153.2 million. Clarity said it expects to be funded for its current clinical program through early 2026.

Its portfolio includes radiopharmaceutical products SAR-bisPSMA, SAR-Bombesin and SARTATE, which are being developed to treat cancers in adults and children.

Executive chairperson Dr Alan Taylor said, "Clarity is very well positioned for what is quickly becoming a radiopharmaceuticals revolution. We are very proud of our achievements to date, and of being the only true Australian radiopharmaceutical company that has developed our products at the benchtop of Australian science.

"More importantly, these novel products are now in a position to change the treatment paradigm for cancer patients around the world, as we are well progressed in our clinical trials in Australia as well as in the largest market in the world, the US. This has been a phenomenal achievement so far for an Australian biotechnology company and the result of the hard work and dedication of our incredible team and collaborators in Australia and the US with the continued support of our shareholders.

“With a strong balance sheet, we are now incredibly excited about continuing our important work as we get closer to our ultimate goal of improving the lives of children and adults with cancer. Importantly, this funding will support the ongoing development of our bisPSMA product. In therapy, through our SECuRE trial, we are seeing responses in patients that have failed up to six lines of therapy prior to being treated with 67Cu-SAR-bisPSMA and we look forward to progressing SECuRE and generating further data on this product. In diagnostics, we are actively recruiting in our registrational Phase III CLARIFY trial in high-risk prostate cancer prior to radical prostatectomy and look forward to commencing our second pivotal Phase III trial in participants with biochemically recurrent (BCR) prostate cancer following positive initial data from our Phase I/II COBRA trial in this patient population. The funding from the capital raise will also enable us to continue progressing clinical trials across our SAR-Bombesin and SARTATE products.

“The remarkable progress with all three of our products in clinical development as well as the exceptional data we are generating in our trials put us in a unique position of having a strong proprietary platform of products in radiopharmaceuticals for first commercial launch in the US. As the sector is undergoing rapid consolidation and the pace of M&A activity accelerates, our team is very excited about Clarity’s future and we look forward to the path ahead.”